# Iclusig PMS in CML or Ph+ALL Patients

> **NCT03709017** · — · UNKNOWN · sponsor: **Korea Otsuka Pharmaceutical Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia
- Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Ponatinib

## Key facts

- **NCT ID:** NCT03709017
- **Lead sponsor:** Korea Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-07
- **Primary completion:** 2022-11-29
- **Final completion:** 2023-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03709017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03709017, "Iclusig PMS in CML or Ph+ALL Patients". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03709017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*